Genomic Medicine Market will evolve to be one of the most dynamic markets of modern medicine because of fast development of genetics that affects the methods of disease diagnosis, treatment planning, and drug discovery throughout the globe. Investment in precision medicine, artificial intelligence, and next generation sequencing technology contributes to the development of genomics in hospitals, research institutes, and pharmaceutical organizations.
According to a recent study by SNS Insider, the global Genomic Medicine Market size valued at USD 33.3 billion in 2025, is anticipated to grow to USD 123 billion by 2035, registering a CAGR of 14.64% over the 2026–2035 forecast period. The market is experiencing the advantages of increased clinical use of genomic technology in oncology and rare diseases, in addition to greater cooperation between biotechnology developers and healthcare providers who want more precise treatment methods.
As the use of genomic data in clinical practice becomes more common, there is increased investment in next generation sequencing technology and digital analysis tools that enhance accuracy in diagnoses and aid in personalized treatments. The development is making genomic medicine an essential element of next-generation health care.
To Get Detailed Insights on the Genomic Medicine Market – Request a Sample Report
Precision Healthcare Expands Beyond Traditional Diagnostics
Healthcare facilities are now going beyond the traditional approach to diagnosis with the inclusion of genomics into disease prevention, treatment options, and management of patients. The development of sequencing techniques has helped reduce the time taken in analysis and improved accessibility for treating difficult health cases.
The use of artificial intelligence is increasing in genome analysis to help scientists detect important genetic variations. With increased abilities in bioinformatics, these technologies are helping healthcare workers make quick, informed decisions in oncology, hereditary problems, cardiovascular diseases, and pharmacogenomics.
Market Segments Reflect Rapid Clinical Adoption
On the basis of application, oncology was the largest segment in 2025 and represented 38% of market revenue as precision oncology continues to gain clinical acceptance around the world. With the increasing availability of advanced genetic testing and early diagnosis of diseases, rare genetic disorders are projected to witness fastest growth through 2035.
In products and services, in 2025, instruments and equipment accounted for approximately 44% market due to continuous investments on sequencing platforms & laboratory infrastructure. At the same time, the services segment is expected to grow fastest as more and more pharmaceutical companies start outsourcing genomic testing, analytical services, and clinical research.
By technology scope, Next-Generation Sequencing (NGS) continued to dominate the market by accounting for nearly 52% of the worldwide revenue share in 2025, owing to its wide application in research and clinical diagnostics. Microarray technologies are predicted to achieve the fastest growth in this period owing to rising applications within gene expression analysis and large-scale genetic screening.
By end user, diagnostic laboratories expected to provide nearly 36% of market revenue in 2025 and pharmaceutical and biotechnology companies projected to experience the most future growth as genomics are more heavily tied into drug discovery/precision therapeutics.
Innovation Continues to Transform Clinical Genomics
The competitive landscape is dynamically changing since industry players are working to create technologies that increase sequencing speed, analytical precision, and clinical accessibility. Decreasing sequencing costs, automation of data processing and analysis pipelines along with cloud-based genomic data analyses are giving health care providers the tools to analyze larger patient populations while also enabling wider spread implementation of personalized medicine efforts.
Innovation is being accelerated by strategic partnerships between biotechnology companies, pharmaceutical manufacturers and research institutions. This is allowing to broaden access to genomic testing, while enhancing the development pipeline for targeted therapies and companion diagnostics.
Regional Markets Strengthen Global Expansion
In 2025, North America continued its lead as the largest regional market in the world with a share of global revenue equivalent to 42.62% due to advanced healthcare infrastructure, higher funding for research activity and early adoption of genomic technologies in the region. The U.S. accounted for about 78% of North America revenue within the region. In the U.S., Genomic Medicine Market for 2025 was valued at USD 9.93 billion and is projected to reach USD32.9 billion by 2035, expanding at a 12.74% CAGR
Rapid growth of the Asia Pacific region is projected during the forecast period, due to rising government investment in biotechnology, precision medicine and healthcare modernization. Regional revenue in China represented nearly 42%, as rapid sequencing capacity expansion and increasing clinical uptake continued.
For Europe, the UK accounted for some 30% of regional revenue while Brazil represented 51% of Latin America. The largest share of Middle East & Africa revenue came from the United Arab Emirates, at around 33%, due to continuous healthcare transformation processes.
Industry Leaders Advance Genomic Innovation
More technological milestones for the genomic medicine industry In 2025, Illumina launched the NovaSeq X Plus sequencing platform, which allows higher throughput and reduces cost-per-sequenced-base. Key recent achievements include the approval by the FDA of gene-editing Casgevy with Vertex Pharmaceuticals and CRISPR Therapeutics in December 2023 which is a breakthrough for gene-editing therapies. Thermo Fisher Scientific and Pfizer Inc. announced in May 2023 the launch of NGS-based cancer testing at thousands of more labs globally in over 30 countries. This partnership is helping to advance precision oncology into daily routine practice.
Major companies operating in the global genomic medicine market include Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Oxford Nanopore Technologies plc, Pacific Biosciences of California, Inc., BGI Genomics Co., Ltd., PerkinElmer, Inc., Myriad Genetics, Inc., Invitae Corporation, Exact Sciences Corporation, Bio-Rad Laboratories, Inc., 23andMe, Inc., Nebula Genomics, GenScript Biotech Corporation, Twist Bioscience Corporation, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., and Bluebird Bio, Inc.
An SNS Insider analyst Parry Kardani commented, "Genomic medicine is becoming central to the future of healthcare as precision diagnostics, sequencing technologies, and AI-powered analytics continue to reshape clinical decision-making. Organizations that invest in scalable genomic platforms and collaborative innovation are expected to play a defining role in advancing personalized medicine over the coming decade.
About the Author
Get in touch
